Advert - Vifor Pharma – Case AUTH/3199/5/19

The Appeal Board required Vifor to be audited for failing to comply with undertakings given in two previous cases in relation to the promotion of Ferinject (ferric carboxymaltose), including sending a promotional email without the prior consent of a recipient and the use of misleading claims which favourably differentiated its IV iron from a competitor on the grounds of tolerability. Vifor Pharma was previously ruled in breach of the following clauses of the 2019 Code:


Clause 2         - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 29       - Failing to comply with an undertaking


In both cases Vifor had been previously publicly remanded (February 2021) for its failure to provide accurate and truthful information to the Code of Practice Panel and its disingenuous approach to responding to the complaints. The Appeal Board had also required an audit of Vifor’s procedures in relation to the Code and two further re-audits. At the consideration of the report of the second re-audit and Vifor’s response, the Appeal Board decided that Vifor should be publicly reprimanded for its lack of progress. The Appeal Board also decided that Vifor should be re-audited in September/October 2022.